Get a Sample
Schedule a Meeting
Get a Sample
Table Of Content
January 2025
The global biomarker discovery outsourcing services market size is calculated at USD 17.42 billion in 2025 and is forecasted to reach around USD 86.74 billion by 2034, accelerating at a CAGR of 19.53% from 2025 to 2034. The North America market size surpassed USD 5.83 billion in 2024 and is expanding at a CAGR of 19.67% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
The global biomarker discovery outsourcing services market size accounted for USD 14.57 billion in 2024 and is predicted to increase from USD 17.42 billion in 2025 to approximately USD 86.74 billion by 2034, expanding at a CAGR of 19.53% from 2025 to 2034. The market is experiencing steady growth, driven by rising precision medicine demand and advanced diagnostic innovations.
The biomarker discovery outsourcing services market encompasses research and analytical solutions offered by contract research organizations (CROs), academic institutions, and biotech firms to identify and validate biomarkers for drug development, diagnostics, and precision medicine. Biomarkers, measurable biological indicators, play a pivotal role in predicting disease progression, monitoring treatment efficacy, and developing companion diagnostics.
Outsourcing these services allows pharmaceutical and biotechnology companies to reduce in-house R&D burden, accelerate timelines, and gain access to advanced platforms such as genomics, proteomics, transcriptomics, and metabolomics. The rise of AI-driven bioinformatics, the integration of a multi-omics approach, and increased focus on oncology and neurological research drive demand.
Artificial intelligence is shaping the way we think about outsourcing biomarker discovery by providing fast, exact interpretation of complex biological data. In November 2024, PathAI made a significant step forward by launching PathExplore Fibrosis, an AI-enabled tool that estimates fibrosis, collagen, and fiber structures using standard H&E-stained whole-slide images. This impressive tool, which forgoes complicated workflows, ancillary stains, skips multiplexing, and provides reproducible and scalable insights into the tumor microenvironment, will help oncology researchers understand patterns of fibrosis that may inform the therapeutic response or impact their disease progression. AI tools such as this, especially with vendors like PathAI pushing the envelope, are quickly becoming a mainstay in our thinking around outsourced biomarker services and translating products into accurate solutions at lower costs, so we can get new drugs to patients and improve personalized medicine. (Source: https://www.drugdiscoverytrends.com)
The U.S. biomarker discovery outsourcing services market size was exhibited at USD 4.08 billion in 2024 and is projected to be worth around USD 24.77 billion by 2034, growing at a CAGR of 19.76% from 2025 to 2034.
Is North America Leading the Biomarker Discovery Outsourcing Services Market?
North America is dominating the biomarker discovery outsourcing services market, supported by its strong innovation ecosystem and research infrastructure. North America has approximately 50% of the global biotech start-up companies, making it a market leader, and continues to lead the world in the number of biomarker-related patents filed. As. Modern omics platforms, AI-driven automation, and a robust regulatory framework enable pharmaceutical and biotech companies to outsource biomarker discovery to specialized CROs geographically dispersed throughout North America.
The United States continues to be the dominant driver of growth for North America's biomarker outsourcing market due to high R&D intensity and the vast number of elite CROs. The United States hosts the largest number of biomarker-related clinical trials. Further, the U.S. government expedited biomarker adoption with major initiatives such as the Cancer Moonshot program and funding for precision medicine to be more widely implemented. With strong academic partnerships, level of AI capabilities, and a clear regulatory path from the FDA, the U.S. continues to influence outsourced biomarker discovery practices and emerging global trends.
Why Is Asia Pacific the Fastest-Growing Region in the Biomarker Discovery Outsourcing Services Market?
Asia-Pacific emerged as fastest fastest-growing region in 2024, with it being a cost-benefit area for the outsourcing marketplace and rapidly growing biotech clusters and government investment for life sciences. The maximum global clinical trials were conducted in Asia-Pacific, with China, India, Australia, Japan, South Korea, and Singapore accounting for nearly 40,000 trials (39,843* in total) from 2020 to mid-2025. This also shows that the Asia-Pacific is a growing factor for biomarker-driven studies with plans to expand even more. AI-powered biomarker analytics are also being utilized more regularly. The trusted availability of large and different patient populations leads to better and more accurate tests, bolstering Asia-Pacific as a preferred area for global biomarker discovery, outsourcing partnerships. (Source: https://www.biospectrumasia.com)
China is firmly in the lead, since it's become the largest base for CROs and biotech collaborations in Asia-Pacific, growing also with the national Precision Medicine plans. There is a greater trend locally; companies are engaging with multinational pharma companies to pursue predictive and companion diagnostic biomarker projects faster. All of these trends, combined with the rapid expansions of AI-enabled omics research and recent regulatory reforms, China is extending its lead for biomarker outsourcing, while providing all of the scale and innovation for drug developers globally.
| Report Coverage | Details |
| Market Size by 2034 | USD 86.74 Billion |
| Market Size in 2025 | USD 17.42 Billion |
| Market Size in 2024 | USD 14.57 Billion |
| Market Growth Rate from 2025 to 2034 | CAGR of 19.53% |
| Dominating Region | North America |
| Fastest Growing Region | Asia Pacific |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Segments Covered | Service Type, Technology Platform, Biomarker Type, Therapeutic Area, End User, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Is the growth in R&D investment in biopharmaceuticals driving biomarker discovery outsourcing?
The biomarker discovery outsourcing services market is triply impacted by the increase in R&D investment in biopharmaceuticals. As innovative therapies are needed to keep pace with the high demand in the marketplace, the global pharma and biotech companies are increasing drug development budgets and precision medicine initiatives. The way biomarkers are integrated into clinical trials can enhance clinical trials by improving patient stratification and limiting the number of failures in drug development pipelines.
The ability to outsource these R&D services gives firms access to value-added services and labor skills, leading to molecular laboratories and the latest technology, along with enabling the firm to optimize costs. Because globally, biopharma R&D spending exceeded $940 billion in 2023, with firms like Pfizer, Novartis, and others expanding their biopharma R&D projects relating to biomarkers, this is increasingly accelerating firms' reliance on their outsourcing partners to foster innovation and maintain their competitive advantage. (Source: https://ncses.nsf.gov)
Are advanced biomarker technologies expensive enough to limit outsourcing again?
The service industry in biomarker discovery is encountering a major impediment in the form of growing costs associated with advanced technologies. Next-generation sequencing (NGS), high-throughput proteomics, and multi-omics seem fundamental and mainstream to precision medicine, but these technologies require a significant commit per project. In 2024, several different pharma companies pointed out that the outsourcing costs for complex biomarker panels were 2x higher than traditional assays, and there are implications for budget allowances by mid-tier firms.
Smaller biotech likely would not have the opportunity to even utilize services at their current pricing levels; this is an impediment for early-stage research. Moreover, outsourcing providers leverage private investment funding in the industry, as high costs are passed on from capital costs of specialized instruments and highly trained personnel.
Are the rising cancer cases and precision therapies providing a greenlight to outsource biomarkers?
The growing cancer burden seen worldwide, coupled with the industry's apparent shift to personalized medicine, shows an enormous opportunity for outsourcing services for oncology biomarker discovery. Cancer treatment today relies heavily on biomarkers for early diagnosis, prognostic risk, and mapping patients to targeted therapy options. Development of these biomarkers requires expensive infrastructure, technology, bioinformatics skills, and funding, prompting companies in pharmaceuticals and biotech to partner and discover through specialized outsourcing service providers.
New data by WHO (2024) indicating over 35 million new cases of cancer by 2050, accentuates the importance of biomarker-based value creation in our search for innovative drug discovery solutions. Outsourcing oncology biomarker discovery gives firms the ability to advance their oncology drug pipelines while increasing their operating efficiencies and scientific accuracy, and allows biomarker development, presenting an important opportunity. (Source: https://www.who.int)
Why does Biomarker Identification Have the Largest Biomarker Discovery Outsourcing Services Market Share?
In the biomarker discovery outsourcing services market, the biomarker identification segment led the market in 2024. Pharmaceutical and biotech firms rely heavily on outsourced partners to identify new biomarkers associated with disease progression and therapeutic response. The increasing focus on precision medicine and early-stage research support is underway, and increasing demand for biomarker identification services, allowing for continued dominance in the landscape.
The companion diagnostics development segment is projected to be the service type accelerating the most rapidly, driven by the integration of targeted therapies into practice and regulator requirements for a diagnostic test when a drug is introduced. The outsourcing providers will again play a key role in co-developing these solutions. With advancements in genomic sequencing and biomarker validation, this segment will grow quickly and represent strong opportunities for innovation and partnerships in the coming years.
Which Genomics (NGS) Dominates the Biomarker Discovery Outsourcing Services Market in 2024?
The genomics segment dominated the market in 2024, with the next-generation sequencing (NGS) sub-segment accounting for around 35% revenue share, as it enables the comprehensive profiling of genetic variation associated with disease mechanisms. Outsourcing providers are heavily involved in offering genomics-based biomarker discovery solutions because of their accuracy, scalability, and ability to provide high-throughput data. The increasing use of NGS in oncology, rare disease, and pharmacogenomics keeps genomics at the forefront of biomarker discovery.
The multi-omics approaches segment is likely to be the next fastest growing technology segment, as they utilize genomics, proteomics, metabolomics, and transcriptomics to greater examine biological systems and relationships. Outsourcing partners who have fully developed multi-omics methods provide advanced analytical frameworks to facilitate precision medicine initiatives for both the pharmaceutical as well as biotechnology pipeline development, and will continue to assure significant growth across both pipelines.
Which Biomarker Type Dominated the Biomarker Discovery Outsourcing Services Market in 2024?
The diagnostic biomarkers segment was the leading segment in the biomarker discovery outsourcing services market, as they help identify disease, monitor patients, and drive treatment decisions. Pharmaceutical and biotech companies hire third-party organizations for the discovery and validation of diagnostic biomarkers to increase precision and minimize timelines. The increased role of diagnostic biomarkers in oncology, infectious diseases, and cardiovascular indications is helping to increase demand, making them the most common type of biomarker used in outsourced research.
The predictive biomarkers segment will have the quickest growth in the near future as they play a critical role in measuring a patient's response to our therapy; predictive biomarkers are increasingly being used in the drug development process as part of the global shift to precision medicine, since they can help with more optimal clinical outcomes. Furthermore, third-party or outsourced partners can provide important input into the evaluation of predictive biomarkers and help with regulatory compliance, helping drive quicker adoption for adjuvant use in both targeted drug development and companion diagnostic development.
Which Therapeutic Area is the Most Dominant in the Biomarker Discovery Outsourcing Services Market?
The oncology segment dominated the market in 2024, with the solid tumors sub-segment holding around 50% revenue share. This is because of the global burden of cancer and the need for effective and rapid solutions utilizing biomarker-driven approaches. Pharmaceutical companies are increasingly relying on outsourced discovery of oncology-focused biomarkers, which often improves the efficacy of drug candidates, expedites clinical trials, and enables patient stratification. By investing heavily in immuno-oncology and targeted therapy development, it further consolidates the segmented area of outsourced research and related services in oncology.
The neurology segment is likely to expand quickly, particularly the neurodegenerative sub-segment. The increasing prevalence of conditions like Alzheimer’s and Parkinson’s has led to the customization of novel biomarkers that improve early detection and monitoring of trials. Providers are increasingly looking to new capabilities such as incorporating proteomics and neuroimaging into biomarker development to help fulfill unmet needs, resulting in rapid growth of the neurology-based biomarker outsourcing sector.
Which End-User Segment Dominated the Biomarker Discovery Outsourcing Services Market in 2024?
The pharmaceutical companies segment dominated the end user in the biomarker discovery outsourcing services market in 2024 due to their high-level investments in biomarker discovery to support drug development pipelines, as well as for regulatory approval. Pharmaceutical companies have always heavily depended on outsourcing. Their prioritization of oncology, precision medicine, and companion diagnostics will certainly keep them as the most important customer base going forward. the biotechnology companies segment is expected to be the fastest-growing end-user segment. Biotechs tend to be very nimble and innovative in the targeted therapy and niche diagnostics space. We see biotechnology firms beginning to increasingly partnering with their outsourcing providers to accelerate the biomarker discovery process, especially in early-stage research and multi-omics research. The biotechnology industry is acquiring more funding, and collaborations are expanding the role of biotech firms, mainly in the space. Biotech is driving fast outsourcing growth in the biomarker discovery segment.
The early stage of discovery often incorporates high-throughput methods in conjunction with genomic and proteomic analyses to harvest biomarkers. Many drug companies and biotechs utilize service providers with proven specialized methods, thus saving on costs and timelines.
The biomarkers discovered will undergo robust validation and assay development to verify that an accessible biomarker is reliable. Service providers will maximize the use of advanced bioinformatics, assuring accuracy and reproducibility, while remaining compliant with increasingly stringent regulatory and clinical trial standards.
Working with pharmaceutical companies, contract research organizations (CROs), and academic partners increases expertise, enhances drug development times, and provides access to amazing biomarker innovations in diagnostics and personalized medicine.
Validated biomarkers are developed into diagnostic products, or companion diagnostics. The commercialization strategy focuses on healthcare providers, but it becomes increasingly regulated, with more frameworks and protocols globally.
By Service Type
By Technology Platform
By Biomarker Type
By Therapeutic Area
By End User
By Region
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
January 2025
October 2024
November 2024
October 2024